Popular Anti-acid Drugs May Contain a Compound That is Proven To Cause Cancer

Over 60 million Americans that take anti-acid reflux medications may be at risk of having developed stomach or bladder cancer

Monday, April 6, 2020 - It seems as if every day another drug whose safety we have taken for granted for years is suspected of causing a disease that is worse than the condition it was intended to treat. Television and print advertising designed to maximize sales highlight the benefits of the drugs making the public think it is safe while barely mentioning the drug's potential side effects. Even commercials that do mention a drug's side effects, usually do so at the very end and do not give them the weight they deserve. Take for example Zantac, an anti-heartburn drug taken by millions of individuals to treat periodic episodes of gastroesophageal reflux disease (GERD), better known as acid reflux. Zantac is the latest in a serious of presumably safe drugs that are now suspected of containing a carcinogen that is known to cause stomach and bladder cancer. Acid-reflux sufferers that have taken Zantac and other anti-acid medications and subsequently developed cancer should consult a heartburn drug cancer attorney to see if they qualify to file a claim against the drug's manufacturers for negligence and for failing to adequately test the drug before offering it to the public.

According to Breast Cancer.org, "FDA Warns About Probable Carcinogen in Zantac. On Sept. 13, 2019, the U.S. Food and Drug Administration (FDA) warned that some ranitidine medicines, including the medicine commonly known as Zantac, contain very low levels of a compound called N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen based on lab testing." The FDA warns companies that like Sanofi, a division of Novartis, and the maker of Zantac to consider voluntarily recalling drugs that contain high levels of NDMA. "The FDA has advised companies to recall their ranitidine if testing shows levels of NDMA above the acceptable daily intake." Zantac is a ranitidine medication used to treat stomach ulcers, heartburn, and acid reflux. The FDA is not advising patients to stop using acid-reflux medications but is advising people to seek the advice of their doctor to recommend other treatment options such as those sold under the brand names Axid (nizatidine), Pepcid (famotidine), and Tagamet (cimetidine).

Bloomberg has reported that the maker of Zantac has stopped producing the popular anti-acid, fueling speculation that the drug may indeed contain a cancer-causing compound, and has recalled the product overseas. "GlaxoSmithKline Plc, the original branded maker of Zantac, halted global distribution of the popular stomach medicine, adding momentum to actions aimed at stopping access to drugs that are tainted with a potential human carcinogen." Walgreens, Rite-Aid, and CVS have discontinued selling ranitidine medications and have pulled them from shelves nationwide.

In addition to Zantac, other PPIs (protein pump inhibitors) and H2 (histamine2) blockers drugs used to reduce stomach acid and available over the counter may cause cancer as well. Those drugs include Prilosec, Prevacid, and Nexium.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
• Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
• Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
• A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
• Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
• Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
• Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
• Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
• The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
• Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
• Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
• Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
• Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
• Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
• Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
• Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.